BofA raised the firm’s price target on Neurocrine (NBIX) to $184 from $182 and keeps a Buy rating on the shares. The firm, which highlights that the company expanded their long-term care and psychiatry salesforce teams last September, is looking for FY25 guidance on the Q4 earnings call as well as color on the expected return from the salesforce investment in 2025 and beyond.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $185 from $170 at Morgan Stanley
- NBIX Upcoming Earnings Report: What to Expect?
- Neurocrine price target raised to $176 from $162 at UBS
- Neurocrine initiates Phase 3 registrational program for osavampator in MDD
- Closing Bell Movers: Graco down 5% as earnings, guidance miss